SPH6516 / Shanghai Pharma - LARVOL DELTA

Shanghai Pharmaceuticals (601607.SH): Terminate clinical trials and subsequent development of four R&D projects: B001, B001-A, I022 (combination therapy, first-line treatment for breast cancer) and I022-K [Google translation] (iis.aastocks.com) - "Shanghai Pharmaceuticals...announced that based on a comprehensive assessment of the future market value of the R&D projects, business synergy, and subsequent development investment, it decided to terminate the clinical trials and subsequent development of the four R&D projects B001, B001-A, I022...and I022-K."

Discontinued • Trial termination • Breast Cancer • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Metastases • New P1 trial • Oncology • Solid Tumor